Worksport Ltd 10-Q

Item 1. Financial Statements Condensed Consolidated Balance Sheets (Unaudited) March 31, 2026 December 31, 2025 (Unaudited) ASSETS Current assets Cash and cash equivalents $ 566,583 $ 5,945,894 Accounts receivable, net 480,212 503,971 Other receivable 290,298 278,027 Inventory (Note 3) 11,622,889 9,530,671 Prepaid expenses and other (Note 6) 510,219 530,861 Total current assets 13,470,201 16,789,424 Investments 67,033 67,033 Property and equipment, net (Note 4) 13,340,898 12,688,488 Operating lease right-of-use assets (Note 11) 244,857 272,598 Intangible assets, net (Note 5) 757,812 896,531 Total assets $ 27,880,801 $ 30,714,074 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities Accounts payable $ 2,843,212 $ 3,107,085 Accrued liabilities and other 1,019,465 1,400,730 Accrued compensation 380,825 420,210 Long-term debt, current portion (Note 12) 2,531,178 1,686,809 Lease liability, current portion (Note 11) 115,980 113,012 Total current liabilities 6,890,660 6,727,846 Lease liability, excluding current portion (Note 11) 128,877 159,526 Long-term debt, excluding current portion (Note 12) 884,256 950,481 Total liabilities 7,903,793 7,837,853 Shareholders’ equity Series A, B and Series C preferred stock, $ 0.001 par value, 10,000,000 shares authorized, 100 Series A, 0 Series B, and 427,612 and 427,812 Series C issued and outstanding, respectively (Note 7) 428 428 Series A, B and Series C Preferred Stock, $0.001 par value, 10,000,000 shares authorized, 100 Series A, 0 Series B, and 427,614 and 427,812 Series C issued and outstanding, respectively (Note 7) 428 428 Common stock, $ 0.001 par value, 45,000,000 shares authorized, 11,925,471 and 9,814,665 shares issued and outstanding, respectively (Note 7) 11,925 9,814 Additional paid-in capital 107,537,779 101,357,686 Share subscriptions receivable ( 1,577 ) ( 55,684 ) Share subscriptions payable 2,166,063 5,446,347 Accumulated deficit ( 89,729,030 ) ( 83,873,790 ) Cumulative translation adjustment ( 8,580 ) ( 8,580 ) Total shareholders’ equity 19,977,008 22,876,221 Total liabilities and shareholders’ equity $ 27,880,801 $ 30,714,074 See accompanying Notes to Condensed Consolidated Financial Statements which form an integral part of the Condensed Consolidated Financial Statements. 3 Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) 2026 2025 Three Months ended March 31, 2026 2025 Net sales $ 3,312,800 $ 2,240,005 Cost of sales 2,458,854 1,843,784 Gross profit 853,946 396,221 Operating expenses Research and development 205,333 369,601 General and administrative 4,239,154 3,414,822 Sales and marketing 2,155,867 869,749 (Gain) loss on foreign exchange ( 2,231 ) ( 1,645 ) Total operating expenses 6,598,123 4,652,527 Loss from operations ( 5,744,177 ) ( 4,256,306 ) Other income (expense) Interest expense ( 92,383 ) ( 195,438 ) Other 8,038 ( 8,720 ) Total other income (expense) ( 84,345 ) ( 204,158 ) Net loss $ ( 5,828,522 ) $ ( 4,460,464 ) Loss per share (basic and diluted) (Note 13) $ ( 0.54 ) $ ( 1.05 ) Weighted average number of shares (basic and diluted) 10,778,204 4,262,474 See accompanying Notes to Condensed Consolidated Financial Statements which form an integral part of the Condensed Consolidated Financial Statements. 4 Condensed Consolidated Statements of Shareholders’ Equity (Unaudited) Shares Amount Shares Amount Capital Receivable Payable Deficit Adjustment (Deficit) Preferred Stock Common Stock Additional Paid-in Share Subscriptions Share Subscription Accumulated Cumulative Translation Total Stockholders’ Shares Amount Shares Amount Capital Receivable Payable Deficit Adjustment Equity Balance at January 1, 2025 100 $ - 4,016,205 $ 4,016 $ 79,781,674 $ ( 1,577 ) $ 2,115,064 $ ( 64,476,966 ) $ ( 8,580 ) $ 17,413,631 Issuance for services and subscriptions payable - - 1,033 1 579,445 - 22,170 - - 601,616 Shares issued (Note 7) - - 22,725 22 185,852 - - - - 185,874 Warrant exercise (Note 14) - - 755,558 756 3,579,763 - 2,804,321 - - 6,384,840 Net loss - - - - - - - ( 4,460,464 ) - ( 4,460,464 ) Balance at March 31, 2025 100 $ - 4,795,521 $ 4,795 $ 84,126,734 $ ( 1,577 ) $ 4,941,555 $ ( 68,937,430 ) $ ( 8,580 ) $ 20,125,497 Balance at January 1, 2026 427,912 $ 428 9,814,665 $ 9,814 $ 101,357,686 $ ( 55,684 ) $ 5,446,347 $ ( 83,873,790 ) $ ( 8,580 ) $ 22,876,221 Balance 427,912 $ 428 9,814,665 $ 9,814 $ 101,357,686 $ ( 55,684 ) $ 5,446,347 $ ( 83,873,790 ) $ ( 8,580 ) $ 22,876,221 Issuance for services and subscriptions payable - - - - 712,822 - 34,868 - - 747,690 Shares issued (Note 7) - - 1,468,606 1,469 2,152,761 - - - - 2,154,230 Shares issued (Note 14) - - 642,000 642 3,314,510 - ( 3,315,152 ) - - - Proceeds from escrow pursuant to Reg-A - - - - - 54,107 - - - 54,107 Series C preferred stock conversions ( 200 ) - 200 - - - - - - - Dividends payable to Series C Preferred shareholders (Note 7) - - - - - - - ( 26,718 ) - ( 26,718 ) Net loss - - - - - - - ( 5,828,522 ) - ( 5,828,522 ) Balance at March 31, 2026 427,712 $ 428 11,925,471 $ 11,925 $ 107,537,779 $ ( 1,577 ) $ 2,166,063 $ ( 89,729,030 ) $ ( 8,580 ) $ 19,977,008 Balance 427,712 $ 428 11,925,471 $ 11,925 $ 107,537,779 $ ( 1,577 ) $ 2,166,063 $ ( 89,729,030 ) $ ( 8,580 ) $ 19,977,008 See accompanying Notes to Condensed Consolidated Financial Statements which form an integral part of the Condensed Consolidated Financial Statements. 5 Condensed Consolidated Statements of Cash Flows (Unaudited) Three Months ended March 31, 2026 2025 CASH FLOWS FROM OPERATING ACTIVITIES Net loss $ ( 5,828,522 ) $ ( 4,460,464 ) Adjustments to reconcile net loss to net cash from operating activities: Shares, options and warrants issued for services 747,690 608,353 Depreciation and amortization 426,229 444,966 Change in operating lease 60 4,100 Adjustments to reconcile net income loss to cash provided by (used in) operating activities ( 4,654,543 ) ( 3,403,045 ) Changes in operating assets and liabilities (Note 10) ( 3,580,211 ) ( 436,873 ) Net cash provided by (used in) operating activities ( 8,234,754 ) ( 3,839,918 ) CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment ( 103,643 ) ( 201,459 ) Purchase of intangible assets - ( 256,883 ) Net cash provided by (used in) investing activities ( 103,643 ) ( 458,342 ) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from issuance of common stock, net of issuance cost 2,154,230 179,137 Proceeds from issuance of Reg-A units, net of issuance cost 54,107 - Proceeds from warrant exercise - 6,384,840 Proceeds from line of credit 4,196,292 110,821 Repayments on line of credit ( 3,366,701 ) ( 2,131,871 ) Repayments on long-term debt ( 51,447 ) ( 47,394 ) Dividends paid to Series C Preferred shareholders ( 27,395 ) - Net cash provided by (used in) financing activities 2,959,086 4,495,533 Increase (decrease) in cash and cash equivalents ( 5,379,311 ) 197,273 Cash and cash equivalents - beginning of period 5,945,894 4,883,099 Cash and cash equivalents - end of period $ 566,583 $ 5,080,372 SUPPLEMENTAL CASH FLOW INFORMATION Income tax paid $ - $ - Interest paid $ 92,000 $ 140,000 Non-cash investing activities and financing activities Capital expenditures included in accounts payable $ 878,537 $ - See accompanying Notes to Condensed Consolidated Financial Statements which form an integral part of the Condensed Consolidated Financial Statements. 6 Notes to the Condensed Consolidated Financial Statements (Unaudited) Note 1- Description of Business and Significant Accounting Policies The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, all adjustments consisting of normal recurring adjustments considered necessary for the fair presentation of results for the interim period have been included. The results of operations for the three months ended March 31, 2026 are not necessarily indicative of the results expected for the full year. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in our Form 10-K for the fiscal year ended December 31, 2025. All references to years in these financial statements are fiscal years. Reclassifications Certain prior year amounts have been reclassified to conform to the current year’s presentation. The Company reclassified professional fees of $ 426,041 for the three months ended March 31, 2025 from professional fees to general and administrative expense in the condensed consolidated statements of operations and comprehensive loss. This change better aligns the nature of the expenses that support the Company’s administrative efforts. The Company reclassified interest income of $ 8,134 for the three months ended March 31, 2025 from interest income to other in the condensed consolidated statements of operations and comprehensive loss to conform with current year presentation. Recent accounting pronouncements Recent accounting pronouncements not yet adopted In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures. This ASU enhances disclosure of specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on the financial statements and related disclosures. In September 2025, the FASB issued ASU 2025-06, Intangibles – Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software . This ASU removes all references to prescriptive and sequential software development stages and will now require public business entities to start capitalizing software costs when management has authorized and committed to funding the software project and is probable that project will be completed and the software will be used to perform the function intended. The ASU also specifies that the disclosures in Subtopic 360-10, Property, Plant and Equipment – Overall, are required for all capitalized internal-use software costs. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the disclosure requirements of this standard and the impact on its consolidated financial statements. In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow Scope Improvements . This ASU amends Topic 270 by improving the navigability of the required interim disclosures and clarifying when the guidance is applicable. The amendment provides additional guidance on when disclosures should be provided in interim reporting periods and requires entities to disclose events since the end of the last annual reporting period that have a material impact on the Company. ASU 2025-11 is effective for interim reporting periods within annual reporting periods beginning after December 15, 2026, with early adoption permitted. The Company is currently evaluating the disclosure requirements of this standard and the impact on its consolidated financial statements. The Company considers the applicability and impact of all ASUs. ASUs not listed were assessed and determined to be either not applicable or had or are expected to have an immaterial impact on the financial statements and related disclosures. 7 Note 2 - Going Concern As of March 31, 2026, the Company had $ 566,583 in cash and cash equivalents. The Company also has availability on its revolving line of credit of $ 2,479,490 . The Company has generated only limited revenues and has relied primarily upon capital generated from public and private offerings of its securities. Since the Company’s acquisition of Worksport in 2014, it has never generated a profit. As of March 31, 2026, the Company had an accumulated deficit of $ 89,729,030 . The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. During the three months ended March 31, 2026, the Company had net losses of $ 5,828,522 (2025 - $ 4,460,464 ). As of March 31, 2026, the Company had working capital of $ 6,579,541 (December 31, 2025 – $ 10,061,578 ) and had an accumulated deficit of $ 89,729,030 (December 31, 2025 - $ 83,873,790 ). The Company has not generated profit from operations since inception and to date has relied on debt and equity financing for continued operations. The Company’s ability to continue as a going concern is dependent upon the ability to generate cash flows from operations and obtain equity and/or debt financing. The Company intends to continue funding operations through equity and debt financing arrangements, which may be insufficient to fund its capital expenditures, working capital and other cash requirements in the long term. There can be no assurance that the steps management is taking will be successful. The Company has historically operated at a loss, although that may change as sales volumes increase and margins improve. As of March 31, 2026, the Company had cash and cash equivalents of $ 566,583 (December 31, 2025 - $ 5,945,894 ). Despite the Company having completed its purchasing of large manufacturing machinery for phase one output levels, operational costs are expected to remain elevated and, thus, further decrease cash and cash equivalents. Concurrently, the Company intends to continue its ramp-up of manufacturing and increasing sales volumes in 2026, which should mitigate the effects of operational costs on cash and cash equivalents as it releases new product lines; this view is supported by the fact that the manufacturing facility of the Company was completed for initial production output in 2023 and quickly began improving output and sales beginning in 2024 and continuing into 2026. The Company has successfully raised capital in recent periods and believes it is positioned to do so again if deemed necessary or strategically advantageous. On September 30, 2022, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company could offer and sell shares of its common stock having an aggregate offering price of up to $ 13.0 million through Wainwright as sales agent under the Company’s shelf registration statement on Form S-3 (File No. 333-267696), including the related base prospectus and prospectus supplement dated October 13, 2022. Sales of shares of common stock through Wainwright, if any, were made pursuant to an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended. Under the ATM Agreement, Wainwright is entitled to a commission equal to 3.0 % of the gross proceeds from shares sold under the ATM Agreement, and the Company also agreed to reimburse Wainwright for certain specified expenses. Because the Company’s public float was below $75.0 million, sales under the ATM Agreement were subject to the limitations of General Instruction I.B.6 of Form S-3. Accordingly, on November 5, 2024 and December 13, 2024, the Company filed prospectus supplements to update the amount of securities then eligible for sale under the ATM Agreement based on the Company’s public float and prior sales during the applicable rolling 12-month period. The Company’s registration statement on Form S-3 (File No. 333-267696) expired on October 13, 2025. Through the expiration date, the Company had sold 872,027 shares of common stock under the ATM Agreement for aggregate gross proceeds of approximately $ 6,751,381 . On November 14, 2025, the Company and Wainwright entered into an amendment to the ATM Agreement in connection with the Company’s new shelf registration statement on Form S-3 (File No. 333-291582). Pursuant to the amended ATM Agreement and the related base prospectus and prospectus supplement dated December 12, 2025, the Company may offer and sell shares of its common sto ck having an aggregate offering price of up to $ 4.0 million through Wainwright as sales agent. Because the Company’s public float remains below $75.0 million, sales under the ATM Agreement remain subject to the limitations of General Instruction I.B.6 of Form S-3, which limits the amount of securities the Company may sell in primary offerings during any rolling 12-month period. During the three months ended March 31, 2026, the Company sold 1,468,606 shares of common stock pursuant to the ATM Agreement for aggregate gross proceeds of approximately $ 2,232,530 , resulting in net proceeds to the Company of approximately $ 2,154,230 after deducting commissions and offering expenses . On November 2, 2023, the Company consummated a registered direct offering pursuant to which the Company issued 192,500 shares of common stock and 157,500 pre-funded warrants to an institutional investor for a total net proceeds of $ 4,261,542 . Concurrently with the registered direct offering, the Company issued the same institutional investor 700,000 warrants in a private sale. The warrants are exercisable for 700,000 shares of common stock for $ 13.40 per share six months after issuance and until five and a half 5.5 years from the issuance date, subject to beneficial ownership limitations as described in the warrants. The Company registered the 700,000 shares of common stock underlying the warrants on a registration statement on Form S-1 (File No. 333-276241) declared effective by the SEC on December 29, 2023. On March 20, 2024, the Company consummated a registered direct offering pursuant to the prospectus supplement dated March 18, 2024 to the Company’s effective shelf registration statement on Form S-3 (File No. 333-267696), pursuant to which the Company issued 237,224 shares of common stock and 147,789 pre-funded warrants to purchase shares of common stock to the same institutional investor as in the Company’s registered direct offering on November 2, 2023, for a total net proceeds of $ 2,629,083 . Concurrently with the registered direct offering, the Company issued the institutional investor 770,026 warrants in a private sale. The warrants became exercisable six months following issuance at an exercise price of $ 7.40 per share and expire five and one-half years from the issuance date, subject to beneficial ownership limitations contained. The Company registered the resale of the 770,026 shares of common stock underlying the warrants pursuant to a registration statement on Form S-1 (File No. 333-278461) which was declared effective by the SEC on April 8, 2024. On May 29, 2024, Worksport sent an inducement letter to a shareholder offering an option to exercise their warrants at a reduced exercise price of $ 5.198 per warrant. In turn, Worksport offered the shareholder new warrants to purchase up to 1,295,000 warrant shares with an exercise price of $ 5.198 . The shares had a term of 5.5 years, with a 6-month required holding period. 8 On February 27, 2025, Worksport entered into a warrant inducement agreement with a shareholder to exercise 755,558 of their 1,295,000 May 2024 Warrants at price of $ 5.198 per share. The remaining unexercised 539,442 warrants are included in share subscription payable. In return, the Company issued 1,424,500 new 2025 Inducement Warrants. Each Inducement Warrant has an exercise price of $ 6.502 , will become exercisable six months after issuance, and have a 5.5 -year life. Worksport raised approximately $ 6,731,000 in gross proceeds before fees and expenses, with the funds earmarked for general corporate and working capital purposes. On June 13, 2025, Worksport completed the initial closing of its Regulation A offering whereby up to 3,100,000 Units may be sold at an offering price of $ 3.25 per unit. Each Unit consists of one share of 8 % Series C Convertible Preferred Stock, par value $ 0.001 per share (the “Series C Preferred Stock”) and one warrant for the right to purchase one (1) share of common stock, $ 0.001 par value with an exercise price of $ 4.50 per share. The qualified Regulation A offering is expected to generate gross proceeds of $ 10,000,000 . The Company completed the Regulation A offering in October 2025. The Company completed 32 tranches and received proceeds of $ 9,092,414 (net of issuance cost of $ 899,997 ). On December 11, 2025, the Company entered into a warrant inducement agreement (the “Inducement”) with the holder of existing warrants to purchase an aggregate of 2,194,526 shares at a reduced exercise price of $ 2.90 . Pursuant to the Inducement, the exercising holder of the existing warrants received 3,840,421 inducement warrants, and the Company received $ 6,364,000 from the exercise of the existing warrants. As a result of the inducement and subsequent exercise, the Company determined the incremental fair value provided to the holder from both the adjustment in exercise price of the existing warrants and the fair value of the inducement warrants issued using the Black Scholes model. The total incremental fair value of $ 4,485,000 is recorded as a non-cash deemed dividend. The proceeds of the warrant inducement and issuance of 916,000 shares of common stock are recorded as additional paid in capital. The obligation to issue the remaining 1,278,526 shares was satisfied during the three months ended March 31, 2026. To date, the Company’s primary sources of liquidity consist of net proceeds from public and private securities offerings and cash exercises of outstanding warrants. Management is focused on transitioning towards revenue as its primary source of liquidity by growing existing product offerings as well as the Company’s customer base. The Company cannot give assurance that it can increase its cash balances or limit its cash consumption and thus maintain sufficient cash balances for planned operations or future business developments. Future business development and demands may lead to cash utilization at levels greater than recently experienced. The Company may need to raise additional capital in the future. However, the Company cannot provide assurances it will be able to raise additional capital on acceptable terms, or at all. The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. Still, certain factors indicate the existence of a material uncertainty that cast substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. These adjustments could be material. Note 3 - Inventories Inventories, net of reserves, consists of: Schedule of Inventories March 31, 2026 December 31, 2025 Raw materials $ 5,417,628 $ 5,405,618 Finished goods 5,347,580 3,368,509 Work in progress 857,681 756,544 Inventories, net $ 11,622,889 $ 9,530,671 Note 4 - Property and Equipment Property and equipment consist of: Schedule of Property and Equipment March 31, 2026 December 31, 2025 Building $ 6,079,410 $ 6,079,410 Manufacturing equipment 6,584,246 6,519,571 Land 2,239,405 2,239,405 Leasehold improvements 503,972 489,722 Product molds 524,476 524,476 Warehouse equipment 527,015 503,297 Electrical equipment 183,977 183,977 Automobile 242,642 242,642 Furniture 149,883 149,883 Computers 101,058 101,058 Construction in progress 879,537 - Property and equipment, at cost 18,015,621 17,033,441 Less accumulated depreciation ( 4,674,723 ) ( 4,344,953 ) Property and equipment, net $ 13,340,898 $ 12,688,488 Construction in progress includes the acquisition and installation of manufacturing equipment to support ongoing production. As of March 31, 2026, the Company had an outstanding contractual obligation of approximately $ 2.1 million related to the acquisition of manufacturing equipment, representing approximately 70% of the total equipment cost of approximately $ 3.0 million. Equipment deposits totaling $ 879,537 are reflected in construction in progress on the condensed consolidated balance sheet. Further, $ 879,537 of capital expenditures related to the equipment were included in accounts payable as of March 31, 2026. The remaining amounts are expected to become due when the equipment is delivered, and installation milestones are achieved. Depreciation expense for the three months ended March 31, 2026 and 2025 was $ 329,770 and $ 348,507 , respectively. 9 Note 5 - Intangible Assets Intangible assets consist of costs incurred to establish the patent rights related to the quick latch and soft vinyl quad-fold tonneau cover technologies, Worksport trademarks, licenses, and software costs. The Company’s utility patents and design registrations were issued between 2014 and 2025. The patents and software are amortized on a straight-line basis over their useful life. The Company’s trademark, licenses, and other indefinite life intangible assets are reassessed every year for impairment. The Company determined that impairment is not necessary for the prior year ended December 31, 2025 and for the three months ended March 31, 2026. The components of intangible assets are as follows: Schedule of Components of Intangible Assets March 31, 2026 December 31, 2025 Software $ 1,150,000 $ 1,150,000 License 218,329 218,329 Patent 62,706 62,706 Trademark 5,150 5,150 Other 201,509 243,769 Intangible assets, gross carrying amount 1,637,694 1,679,954 Less accumulated amortization ( 879,882 ) ( 783,423 ) Intangible assets, net $ 757,812 $ 896,531 Amortization expense for the three months ended March 31, 2026 and 2025 was $ 96,459 for both periods, respectively. Estimated amortization of the patent and software over the next five calendar years and beyond March 31, 2026 is as follows: Schedule of Estimated Amortization of the patent and Software 2026 $ 289,000 2027 $ 3,000 2028 $ 3,000 2029 $ 3,000 2030 $ 3,000 Thereafter $ 32,000 Note 6 - Prepaid Expenses and Other Prepaid expenses and other consist of: Schedule of Prepaid Expenses and Deposits March 31, 2026 December 31, 2025 Consulting, services and advertising $ 329,526 $ 222,922 Insurance 40,960 104,421 Deposits 139,733 203,518 Prepaid expenses and other $ 510,219 $ 530,861 Note 7- Shareholders’ Equity The Company is authorized to issue up to 55,000,000 shares of capital stock, par value $ 0.001 per share. Capital stock is divided into two classes designated as common stock and preferred stock. Common stock – The Company is authorized to issue up to 45,000,000 shares of common stock. Preferred stock – The Company is authorized to issue up to 10,000,000 shares of preferred stock. The board of directors may authorize, without further shareholder action, the issuance of preferred stock in one or more classes or series. Preferred stock ranks senior to common stock with respect to payment of dividends and the distribution of assets on liquidation. Each class or series of preferred stock, when issued, must include its designation and a description of certain rights, including voting privileges, dividend preferences, conversion features, restrictions and redemption rights. - During 2019, the Company created and issued 100 shares of its Series A preferred stock. Series A preferred shareholders vote together as a single class and are entitled to 51% of the voting rights on all matters regardless of the number of Series A preferred shares outstanding. Series A preferred stock does not have conversion rights, is not entitled to receive dividends nor receive any liquidation preferences. - During 2020, the Company created the Series B preferred stock. Series B preferred shareholders have the right to vote for each share of common stock outstanding after the issuance date. Series B preferred stock does not have conversion rights, is not entitled to receive dividend preferences nor receive any liquidation preferences. As of March 31, 2026, the Company has not issued shares of Series B preferred stock. - During 2025, the Company created its Series C preferred stock for its Regulation A offering. Refer to Note 14, Warrants for a description of units available in the Regulation A offering. Series C preferred stock ranks senior to common stock and future classes or series of preferred stock as to dividend and liquidation rights. Series C preferred shareholders may convert holdings on a 1:1 basis to common stock at any time. Series C preferred shareholders are entitled to cumulative dividends at a rate of 8.00% of the $3.25 liquidation preference per share per year for a period of two (2) years from the date of issuance. As of March 31, 2026, the Company issued 3,074,586 shares of Series C preferred stock and converted 2,646,974 Series C preferred shares to common stock at the shareholder’s request. The Company recognized dividends payable to Series C preferred shareholders for the three months ended March 31, 2026 of $ 26,718 . During three months ended March 31, 2026, the following transactions occurred: During the three months ended March 31, 2026, the Company sold an aggregate of 1,468,606 shares of its common stock pursuant to the ATM Agreement for aggregate gross proceeds of $ 2,232,530 , net of issuance costs of $ 78,300 . The shares in a shelf takedown from the Company were sold pursuant to the base prospectus and prospectus supplement filed with the Securities and Exchange Commission as part of the Company’s registration statement on Form S-3 (File No. 333-291582), which was declared effective on December 12, 2025. The Company recognized consulting expense of $ 34,868 for share subscriptions payable from restricted shares to be issued. As of March 31, 2026, the restricted shares have not been issued. The Company also recognized consulting expense of $ 107,833 related to warrants. As of March 31, 2026, the warrants vested and were issued. Transactions reflected in consulting expense are included as a component of general and administrative expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss. 10 Refer to Note 14, Warrants and Note 15, Equity Compensation for additional disclosures related to shareholders’ equity. During three months ended March 31, 2025, the following transactions occurred: During the three months ended March 31, 2025, the Company sold an aggregate of 22,725 shares of its common stock pursuant to an At the Market Offering Agreement, dated September 30, 2022, for aggregate gross proceeds of $ 185,874 . The shares were sold pursuant to the Company’s base prospectus and the related prospectus supplements filed with the Securities and Exchange Commission as part of the Company’s registration statement on Form S-3 (File No. 333-267696), which was declared effective on October 13, 2022. The Company recognized consulting expense of $ 22,017 to share subscriptions payable from restricted shares and stock options to be issued. As of March 31, 2025, the restricted shares have not been issued. Transactions reflected in consulting expense are included as a component of general and administrative expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss. During the three months ended March 31, 2025, the Company issued 1,000 restricted shares with a value of $ 82,100 . During the three months ended March 31, 2025, in connection with the inducement of 1,295,000 warrants at $ 5.198 per share, the Company also sold 1,424,500 warrants exercisable at $ 6.502 per share. The Company received proceeds of $ 6,731,410 before deducting placement agent fees of $ 346,570 and other offering expenses payable by the Company upon the exercise of the May 2024 Existing Warrants. Note 8 - Income Taxes The effective tax rate for the three months ended March 31, 2026 and 2025 was 22.9 % before 100 % allowance adjustments on net deferred income tax assets. The effective tax rate for the three months ended March 31, 2026 and 2025 was higher than expected from applying the U.S. federal statutory rate of 21 % to loss before income taxes due to tax benefits on losses generated outside the U.S. with higher statutory rates. Note 9 - Financial Instruments and Fair Value Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an ordinary transaction between market participants at the measurement date. Depending on the nature of the asset or liability, various techniques and assumptions can be used to estimate fair value. The definition of the fair value hierarchy is as follows: Level 1 – Quoted prices in active markets for identical assets and liabilities. Level 2 – Observable inputs other than quoted prices in active markets for similar assets and liabilities. Level 3 – Inputs for which significant valuation assumptions are unobservable in a market and therefore value is based on the best available data, some of which is internally developed and considers risk premiums that a market participant would require. The Company’s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, revolving line of credit, and long-term debt. The fair values of cash and cash equivalents, accounts receivable, and accounts payable approximate their carrying value because of the short-term nature of these instruments. The Company’s revolving line of credit and long-term debt are based on a variable interest rate, and are reflected in the financial statements at carrying value which approximates fair value at March 31, 2026. The fair value of the revolving line of credit and long-term debt is classified as Level 2 within the fair value hierarchy. The Company is exposed to market risks such as fluctuation in foreign currency exchange rates and interest rates. Derivative instruments may be used to offset some of the effects of these market risks on the expected future cash flows and on certain existing assets and liabilities. The Company may choose not to hedge certain exposures for a variety of reasons including, but not limited to, accounting considerations and the prohibitive economic cost of hedging particular exposures. Market Risks Foreign Currency Risk The Company is exposed to currency risk on its sales and purchases denominated in Canadian Dollars. The Company actively manages these risks by adjusting its pricing to reflect currency fluctuations and purchasing foreign currency at advantageous rates. Interest Rate Risk The borrowing under the Company’s Line of Credit Facility and Equipment Financing is at variable interest rates and exposes the Company to interest rate risk. If interest rates increase, debt service obligations on variable rate indebtedness will increase even though the amount borrowed may not change. 11 Note 10 - Changes in Cash Flows from Operating Assets and Liabilities The changes to the Company’s operating assets and liabilities for the three months ended March 31, 2026 and 2025 are as follows: Schedule of Changes in Operating Assets and Liabilities 2026 2025 Decrease (increase) in accounts receivable $ 23,759 $ ( 25,362 ) Decrease (increase) in other receivable ( 12,271 ) ( 27,015 ) Decrease (increase) in inventory ( 2,092,218 ) ( 583,116 ) Decrease (increase) in prepaid expenses and other 62,902 ( 192,071 ) Increase (decrease) in accounts payable and accrued liabilities ( 1,562,383 ) 390,691 Changes in operating assets and liabilities $ ( 3,580,211 ) $ ( 436,873 ) Note 11 - Leases The Company accounts for leases under ASC 842, whereby it recognizes a lease liability and a right-of-use asset. The lease liability is measured at the present value of the remaining lease payments, discounted by the Company’s incremental borrowing rate. The Company measured the right of use asset at an initial amount equal to the lease liability. On April 1, 2025, the Company signed a lease agreement for 12,500 square feet of office space to be used as a R&D facility pursuant to a three -year lease with an option to extend the lease for an additional two years. The lease was effective on May 1, 2025 at a rate of $ 9,659 per month with a termination date of April 30, 2028 . The Company’s incremental borrowing rate used to initially measure the present value of the remaining lease payments was 15 %. On July 14, 2025, the Company signed a lease agreement for 1,992 square feet of office space to be used as an R&D facility for its Terravis Energy subsidiary pursuant to a two -year lease effective July 18, 2025 for an average monthly rent of $ 3,154 . The Company’s incremental borrowing rate used to initially measure the present value of the remaining lease payments was 15 %. 12 The Company’s right-of-use asset and lease liability as of March 31, 2026, and December 31, 2025, are as follows: Schedule Right-of-use Asset March 31, 2026 December 31, 2025 Right-of-use asset $ 244,857 $ 272,598 Current lease liability $ 115,980 $ 113,012 Long-term lease liability $ 128,877 $ 159,526 The following is a summary of the Company’s total lease costs: Schedule of Lease Cost March 31, 2026 March 31, 2025 Operating lease cost $ 37,138 $ 78,407 The following is a summary of cash paid during the three months ended March 31, 2026 and 2025 for amounts included in the measurement of lease liabilities: Schedule of Measurement of Lease Liabilities March 31, 2026 March 31, 2025 Operating cashflow $ 37,138 $ 78,471 The following are future calendar year minimum lease payments as of March 31, 2026: Schedule of Future Minimum Annual Lease Payments 2026 $ 107,315 2027 134,284 2028 39,784 Total future minimum lease payments 281,383 Less: amount representing interest ( 36,526 ) Present value of future payments 244,857 Current portion 115,980 Long term portion $ 128,877 13 Note 12 - Indebtedness Long-term debt consists of: Schedule of Long Term Debt March 31, 2026 December 31, 2025 Revolving Credit Facility (a) $ 2,260,723 $ 1,441,665 Other (b) 1,177,945 1,233,493 Long-term debt 3,438,668 2,675,158 Less deferred debt issuance cost ( 23,234 ) ( 37,868 ) Less current installments ( 2,531,178 ) ( 1,686,809 ) Long-term debt $ 884,256 $ 950,481 a) On July 19, 2024, the Company, as the guarantor, and Worksport New York Operations Corporation as well as Worksport USA Operations Corporation, entered into a $ 6,000,000 Revolving Financing and Assignment Agreement with an external lending entity with a maturity date of July 18, 2026, or 24 months. Upon transaction close, the Company drew down approximately $ 5.06 million of the Revolving Credit Facility, net of $ 790,000 of interest reserve required to be withheld to ensure interest payments by the Company. The Company used $ 4.73 million of the drawn down amount to refinance the Company’s mortgage on the Company’s real property located at 2500 North America Dr. in West Seneca, New York, and additionally drew approximately $ 330,000 to fund operations. At March 31, 2026, the outstanding balance of this loan was $ 2,260,723 . For collateral, the lender holds a first position on the Company’s major asset classes (accounts receivable, the factory in New York, and inventory) other than the Company’s equipment. A non-usage fee of 0.25 % is assessed quarterly and applied to the difference between the quarter’s average daily outstanding loan balance and the total credit facility amount. As of March 31, 2026, the Company had an available balance of $ 2,479,490 to borrow on the Revolving Credit Facility. b) On September 4, 2024, the Company, through its wholly owned subsidiary, Worksport USA Operations Corporation, entered into a $ 1,487,200 credit and security agreement with an external lending entity with a maturity date of September 1, 2027 , which is 36 months from initial funding. Upon transaction close, the Company received net proceeds of $ 1,412,750 (net of issuance costs of $ 43,735 ). The Company and its wholly owned subsidiary, Worksport New York Operations Corporation, serve as guarantors on the loan. For collateral, the lender holds a first position on the Company’s equipment, which is primarily manufacturing and warehousing equipment. Interest on the loan is based on the prime rate plus 700 basis points per annum. At March 31, 2026, the outstanding balance of this loan was $ 1,154,711 (net of issuance costs of $ 23,234 ). The Company is in compliance with all covenants. Note 13 - Loss per Share For the three months ended March 31, 2026, loss per share is ($ 0.54 ) (basic and diluted) compared to that of the three months ended March 31, 2025, of ($ 1.05 ) (basic and diluted) using the weighted average number of shares of 10,778,204 (basic and diluted) and 4,262,474 (basic and diluted), respectively. There are 45,000,000 common shares authorized with 11,925,471 and 4,795,521 shares issued and outstanding, at March 31, 2026 and 2025, respectively. The computation of loss per share is based on the weighted average number of shares outstanding during the period in accordance with ASC Topic No. 260, “Earnings Per Share.” Shares underlying the Company’s outstanding warrants and convertible promissory notes were excluded due to the anti-dilutive effect they would have on the computation. 14 Note 14 - Warrants On December 11, 2025, the Company entered into a warrant inducement agreement with the holder of existing warrants to purchase an aggregate of 2,194,526 shares at a reduced exercise price of $ 2.90 . Pursuant to the inducement, the existing holder of the existing warrants received 3,840,421 inducement warrants, and the Company received $ 6,364,000 from the exercise of the existing warrants. As a result of the inducement and subsequent exercise, the Company determined the incremental fair value provided to the holder from both the adjustment in exercise price of the existing warrants and the fair value of the inducement warrants issued using the Black Scholes model. The total incremental value of $ 4,485,000 is recorded as a non-cash deemed dividend as a reduction of additional paid in capital based on the Company’s history of net operating losses. The proceeds of the warrant inducement and issuance of 916,000 shares of common stock are recorded as additional paid-in capital. During December 2025, the Company partially satisfied its obligation to issue 636,526 shares of common stock. During January 2026, the Company satisfied its remaining obligation to issue 642,000 shares of common stock. Shares subsequently issued after the inducement agreement are recorded as additional paid-in capital. On September 2, 2025, the Company entered into a consulting agreement with a third party to perform certain services for a six-month period in exchange for both cash consideration and the issuance of warrants. The warrant agreement was issued on March 2, 2026 and is exercisable to purchase up to 100,000 shares for $ 4.00 per share and 100,000 shares of common stock at $ 5.00 per share. The warrants expire two years from the date of issuance. The Company determined the fair value provided to the holder at the date of the consulting agreement using the Black Scholes model, as the warrants were earned by the holder over the term of the consulting agreement. For the fiscal year ended December 31, 2025, the Company recognized $ 216,000 as a component of general and administrative expense. For the three months ended March 31, 2026, the Company recognized $ 108,000 as a component of general and administrative expense. The Company commenced its Regulation A offering pursuant to which it offered up to 3,100,000 units at a price of $ 3.25 per unit. Each unit consisted of one share of 8% Series C Convertible Preferred Stock, par value $0.001 per share (the “Series C Preferred Stock”), and one warrant to purchase one share of common stock, par value $0.001 per share, at an exercise price of $4.50 per share. On June 13, 2025, the Company completed the initial closing of the Regulation A offering. On October 15, 2025, the Company completed the Regulation A offering, pursuant to which it sold an aggregate of 3,074,586 units for gross proceeds of approximately $ 9.99 million, before deducting fees and expenses. The proceeds from the Regulation A offering are recorded as additional paid-in capital. Through March 31, 2026, the Company issued 3,074,586 warrants to investors. During the three months ended March 31, 2026, the Company received $ 54,107 of previously escrowed proceeds related to the Regulation A offering . On February 27, 2025, the Company entered into a warrant inducement agreement (the “Inducement Agreement”) with the holder of existing warrants to purchase an aggregate of 1,295,000 shares for a reduced exercise price of $ 0.5198 per share. Pursuant to the Inducement Agreement, the exercising holder of the existing warrants received 1,425,000 inducement warrants, and the Company received $ 6,731,000 from the exercise of the existing warrants, before deducting placement agent fees and other offering expenses payable by the Company. As a result of the inducement and subsequent exercise, the Company determined the incremental fair value provided to the holder from the inducement warrants issued using the Black Scholes model. The total incremental fair value of $ 7,602,000 , is recorded as a non-cash deemed dividend. The proceeds of the warrant inducement and issuance of 1,295,000 shares of common stock are recorded as additional paid-in capital. The Company registered the shares of common stock issuable upon the exercise of the inducement warrants on a registration statement on Form S-1 (File No. inducement 333-286255 ) declared effective by the Securities and Exchange Commission on April 3, 2025. During the year ended December 31, 2024, in connection with the sale of 237,224 shares of common stock, the Company also sold 147,789 pre-funded warrants and issued 770,026 warrants exercisable for a total of 770,026 shares of common stock for $ 0.001 and $ 7.40 , respectively, per share. The Company received net proceeds of $ 1,093,492 associated with the sale of the pre-funded warrants. The pre-funded warrants are immediately exercisable until all of the pre-funded warrants are exercised. During the same period, 147,789 pre-funded warrants were exercised for 147,789 shares of common stock for $ 150 . 15 During the year ended December 31, 2024, the Company closed a sale of 95,000 shares of common stock. In connection with the sale of common stock, the Company issued 190,000 warrants. The warrants have an exercise price of $ 4.00 and an expiration date of September 21, 2029 . During the year ended December 31, 2024, 13,091 warrants issued on August 3, 2021, and 344,652 warrants issued on August 6, 2021, all of which having an exercise price of $ 60.50 , expired. During the year ended December 31, 2023, in connection with the sale of 192,500 shares of common stock the Company also sold 157,500 pre-funded warrants and 700,000 warrants convertible for 857,500 shares of common stock at an exercise price of $ 0.001 and $ 13.40 , respectively. The Company received net proceeds of $ 2,110,342 associated with the sale of the pre-funded warrants. During the same period, 88,700 pre-funded warrants were exercised for 88,700 shares of common stock for $ 89 . During the year ended December 31, 2024, the remaining 68,800 pre-funded warrants were exercised for 68,800 shares of common stock for $ 69 . On May 9, 2024, the Company entered into a warrant inducement agreement (the “Inducement”) with the holder of existing warrants to purchase an aggregate 700,000 shares at a reduced exercise price of $ 5.198 in consideration for the Company to issue new warrants to purchase up to 1,295,000 additional shares of common stock – resulting in gross proceeds of approximately $ 3,638,000 received by the Company. As a result of the Inducement and subsequent exercise, the Company determined the incremental fair value provided to the holder from both the adjustment in exercise price of the existing warrants and the fair value of the inducement warrants issued using the Black Scholes model. The total incremental fair value of $ 4,996,000 is recorded as a non-cash deemed dividend. The proceeds of the warrant inducement and issuance of 284,000 shares of common stock are recorded as capital in excess of par. The obligation to issue the remaining 416,000 shares was originally recorded as a share subscription payable. During the twelve months ended December 31, 2024, the Company issued 416,000 out of the 416,000 shares to be issued. During the year ended December 31, 2023, the Company and a stock options holder agreed to cancel all 40,000 stock options in exchange for extending the exercisable period of 30,000 warrants to December 31, 2024. Later in the year ended December 31, 2023, the expiration date for these warrants was extended to December 31, 2026, and the stock option holder was issued an additional 40,000 restricted stock units. During the year ended December 31, 2022, the Company and a warrant holder reached an agreement to extend the exercisable period of 30,000 warrants, convertible to 2 shares of common stock each, for an additional 12 months. During the year ended December 31, 2021, the Company issued 13,091 representative warrants to the Company’s underwriters. The representative warrants were not exercisable until January 30, 2022. The representative warrants were exercisable for 13,091 shares of common stock at $ 60.50 per share until August 3, 2024. As of December 31, 2022, the Company recognized a value of $ 273,993 for the representative warrants to share issuance cost. During the year ended December 31, 2024, these representative warrants expired. 16 As of March 31, 2026, the Company has the following warrants outstanding: Schedule of Warrants Exercise Price Exercise price Number outstanding Remaining Contractual Life (Years) Expiry date $ 40.00 30,000 0.75 December 31, 2026 $ 4.00 190,000 3.48 September 21, 2029 $ 3.00 3,840,421 5.20 June 12, 2031 $ 4.00 - 5.00 200,000 1.92 March 2, 2028 $ 4.50 3,074,587 2.21 - 2.57 June 13, 2028 – October 24, 2028 7,335,008 3.88 The average remaining contractual life of outstanding warrants that expire is 3.88 years. Schedule of Warrants Activity March 31, 2026 December 31, 2025 Number of warrants Weighted average price Number of warrants Weighted average price Balance, beginning of year 7,335,008 $ 3.85 2,291,276 $ 6.35 Issuance - $ - 8,539,508 $ 4.16 Expired - $ - ( 6,250 ) $ 24.00 Exercise - $ - ( 3,489,526 ) $ 6.22 Balance, end of period 7,335,008 $ 3.85 7,335,008 $ 3.85 Note 15 - Equity Compensation The Company has adopted three equity incentive plans: the 2015 Equity Incentive Plan, the 2021 Equity Incentive Plan, and the 2022 Equity Incentive Plan. The 2015 Equity Incentive Plan expired in 2025 upon reaching the end of its ten-year term. The 2015 and 2021 plans each authorized a fixed number of shares for issuance. Under the 2022 Equity Incentive Plan, the number of shares of common stock reserved for issuance shall not exceed 18% of the issued and outstanding shares of common stock of the Company. Awards under each plan have a maximum term of 10 years and vest at the discretion of the Board of Directors . All equity-settled, share-based payments are ultimately recognized as an expense in the statement of operations with a corresponding credit to “Additional Paid in Capital.” If vesting periods or other non-market vesting conditions apply, the expense is allocated over the vesting period, based on the best available estimate of the number of share options expected to vest. Estimates are subsequently revised if there is any indication that the number of share options expected to vest differs from previous estimates. Any cumulative adjustment prior to vesting is recognized in the current period. No adjustment is made to any expense recognized in prior periods if share options ultimately exercised are different than that estimated on vesting. 17 Performance Share Units On May 1, 2023, the Company and Steven Rossi reached an agreement to modify 160,000 restricted stock units and 40,000 performance stock units (“PSUs”) issued on November 11, 2022, and December 29, 2021, respectively, and replace them with 200,000 stock options, as described below. On November 11, 2022, 40,000 and 30,000 PSUs granted on December 29, 2021, as described below, were modified to include new terms pertaining to the PSU vesting schedule. The PSUs vest in 5% increments according to the modified schedule that correlates with the Company’s stock price. The first 5% of the PSUs vest upon the Company’s stock price closing at $22.50, 50% will have vested at a closing price of $53.10, and 100% will have vested at a closing price of $137.60 as measured using the volume weighted average of the Company’s common stock for ten (10) consecutive trading days, with over $ 100,000 of trading volume on each of those days. The fair value of the PSUs was estimated to be $ 1,254,460 . As of March 31, 2026, 7,500 PSUs of the remaining 30,000 PSUs had vested, and the Company recognized $ 26,881 (March 31, 2025 - $ 26,881 ) in general and administrative expense. On December 29, 2021, the Company granted 40,000 and 30,000 PSUs to the Company’s Chief Executive Officer and a director, respectively. The PSUs were to vest in 5% increments according to a schedule that correlates with the Company’s stock price. The first 5% of the PSUs was to have vested upon the Company’s stock price closing at $30.00; 50% was to have vested at a closing price of $165.00, and 100% was to have vested at a closing price of $315.00. The fair value of the PSUs was estimated to be $ 1,344,570 . Stock Options The Company uses the Black-Scholes option pricing model to determine fair value of stock options on the grant date. During the three months ended March 31, 2026, the Company issued the following stock options to various directors: - 90,006 stock options vesting ratably over three years, with an exercise price of $ 1.66 and an expiration date of February 9, 2036 During the three months ended March 31, 2026, the Company issued the following stock options to various employees and consultants: - 205,000 stock options vesting over one year, with an exercise price of $ 2.21 and an expiration date of January 5, 2036 - 75,000 stock options vesting ratably over three years, with an exercise price of $ 2.21 and an expiration date of January 5, 2036 - 25,000 stock options vesting pursuant to performance milestones, with an exercise price of $ 2.21 and an expiration date of January 5, 2036 - 15,000 stock options vesting ratably over two years, with an exercise price of $ 1.66 and an expiration date of February 9, 2036 During the three months ended March 31, 2026, the Company issued the following stock options to Steven Rossi: - 240,000 stock options vesting ratably over three years, with an exercise price of $ 1.66 , and an expiration date of February 9, 2036 Schedule of Stock Options Activity March 31, 2026 December 31, 2025 Number of stock Weighted average Number of stock Weighted average options price options price Balance, beginning of year 1,171,706 $ 5.37 579,936 $ 7.14 Granted 650,006 $ 1.94 596,040 $ 3.68 Forfeited ( 1,000 ) $ 3.09 ( 4,270 ) $ 9.52 Balance, end of period 1,820,712 $ 4.12 1,171,706 $ 5.37 Schedule of Share Based Payment Arrangement, Option, Exercise Price Range Range of Exercise Weighted average Weighted average Exercisable on prices Outstanding life (years) exercise price March 31, 2026 Stock options $ 1.66 - 7.042 1,820,712 8.65 $ 4.12 470,563 18 As of March 31, 2026 and December 31, 2025, Terravis Energy Inc., a wholly owned subsidiary of the Company, has the following options outstanding: Schedule of Stock Options Activity March 31, 2026 December 31, 2025 Number of stock Weighted average Number of stock Weighted average options price options price Balance, beginning of year 1,350,000 $ 0.01 1,350,000 $ 0.01 Granted - $ - - $ - Balance, end of period 1,350,000 $ 0.01 1,350,000 $ 0.01 Schedule of Share Based Payment Arrangement, Option, Exercise Price Range Range of Weighted average Weighted average Exercisable on Exercise prices Outstanding life (years) exercise price March 31, 2026 Stock options $ 0.01 1,350,000 6.03 $ 0.01 1,350,000 Note 16 - Segment Reporting The Company manages its business on a product basis and operates in the following two reporting segments for financial reporting purposes: (1) Hard Tonneau Covers and (2) Soft Tonneau Covers. The accounting policies of both reporting segments are the same as those described in Note 1, Description of Business and Summary of Significant Accounting Policies. The Company’s chief operating decision maker (“CODM”) is the Chief Executive Officer, who regularly reviews financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance of the Company’s reporting segments. The CODM primarily focuses on net income (loss) from continuing operations to evaluate its reporting segments. The CODM also uses net income (loss) from continuing operations for evaluating pricing strategy and assessing the performance for determining the compensation of certain employees. Significant segment expenses reviewed, which represent the differences between segment net sales and segment net loss from continuing operations, consist of the following: Schedule of Revenue and Segment Net Loss Hard Tonneau Covers Soft Tonneau Covers Corporate / Eliminations Consolidated Hard Tonneau Covers Soft Tonneau Covers Corporate / Eliminations Consolidated For the three months ended March 31, 2026 For the three months ended March 31, 2025 Hard Tonneau Covers Soft Tonneau Covers Corporate / Eliminations Consolidated Hard Tonneau Covers Soft Tonneau Covers Corporate / Eliminations Consolidated Net sales $ 3,269,705 $ 43,095 $ - $ 3,312,800 $ 2,118,565 $ 121,440 $ - $ 2,240,005 Cost of sales ( 2,429,589 ) ( 29,265 ) - ( 2,458,854 ) ( 1,736,491 ) ( 98,351 ) ( 8,942 ) ( 1,843,784 ) Selling, general and administrative ( 2,742,013 ) ( 29,215 ) ( 3,400,666 ) ( 6,171,894 ) ( 2,023,395 ) ( 66,229 ) ( 2,117,937 ) ( 4,207,561 ) Depreciation and amortization ( 378,443 ) ( 4,552 ) ( 43,234 ) ( 426,229 ) ( 417,316 ) ( 12,829 ) ( 14,821 ) ( 444,966 ) Loss from continuing operations $ ( 2,280,340 ) $ ( 19,937 ) $ ( 3,443,900 ) $ ( 5,744,177 ) $ ( 2,058,637 ) $ ( 55,969 ) $ ( 2,141,700 ) $ ( 4,256,306 ) The following table presents the Company’s net sales disaggregated by geographic area: Schedule of Net Sales Disaggregated by Geographic Area Hard Tonneau Covers Soft Tonneau Covers Consolidated Hard Tonneau Covers Soft Tonneau Covers Consolidated 2026 2025 Hard Tonneau Covers Soft Tonneau Covers Consolidated Hard Tonneau Covers Soft Tonneau Covers Consolidated United States $ 3,263,586 $ 43,059 $ 3,306,645 $ 2,105,908 $ 121,641 $ 2,227,549 Canada 6,119 36 6,155 12,456 - 12,456 Total Net sales $ 3,269,705 $ 43,095 $ 3,312,800 $ 2,118,364 $ 121,641 $ 2,240,005 No asset information has been provided for the reported segments as the CODM does not regularly review asset information by reportable segment. As of March 31, 2026 and December 31, 2025, assets held in the U.S. accounted for 93 % of total assets for each period, respectively. Note 17 - Commitments and Contingencies There are no legal proceedings except for routine litigation incidental to the business. Note 18 - Subsequent Events The Company has evaluated subsequent events through May 13, 2026. The following events occurred after the three months ended March 31, 2026: ● On April 13, 2026, the Company issued to its Chief Executive Officer, Steven Rossi, 88,214 shares of the Company’s common stock, par value $ 0.001 per share at a deemed price of $ 0.8502 per share, representing the closing price of the Company’s Common Stock on the Nasdaq Capital Market on April 10, 2026, for an aggregate value of $ 75,000 . The shares were issued in satisfaction of previously accrued and unpaid bonus compensation owed to Mr. Steven Rossi and were approved by the Company’s Board of Directors. ● On April 20, 2026, the Company announced the official commercial launch and commencement of sales for the NEXUS Tonneau Cover. Production began on April 13, 2026. ● On April 29, 2026, the Company announced that it secured Tri-State Enterprises, Inc. (“Tri-State”) as a new cross-regional distribution partner for the Company’s growing tonneau cover lineup, including the Company’s recently launched NEXUS cover. ● On April 30, 2026, Michael Johnston resigned as the Company’s Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective April 30, 2026. Mr. Johnston’s resignation was not the result of any disagreement with the Company regarding its operations, policies or practices, including any matters relating to the Company’s accounting practices or financial reporting. ● On April 30, 2026, the Company’s Board of Directors appointed Jennifer Kartychak as the Company’s Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective May 1, 2026. Ms. Kartychak has served as the Company’s Vice President of Finance since January 1, 2026. Prior thereto, beginning in August 2023, Ms. Kartychak provided consulting services to the Company through Arend Advisory Group LLC, an entity wholly owned by Ms. Kartychak. ● Through May 13, 2026, the Company sold and issued 606,069 of common stock in consideration for net proceeds of $ 623,124 under the ATM Agreement. 19